Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment
- 30 May 2020
- journal article
- research article
- Published by Elsevier BV in Clinical Neurology and Neurosurgery
- Vol. 196, 105976
- https://doi.org/10.1016/j.clineuro.2020.105976
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in GliomasJournal of Clinical Oncology, 2009
- Influence of Inflammation-Based Prognostic Score on Mortality of Patients Undergoing Chemotherapy for Far Advanced or Recurrent Unresectable Colorectal CancerAnnals of Surgery, 2009
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- Prognostic and clinical implication of IL-6 expression in glioblastoma multiformeJournal of Clinical Neuroscience, 2005
- Inhibition of Albumin Synthesis in Chronic DiseasesJournal of Clinical Gastroenterology, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survivalJournal of Neurosurgery, 2001
- CYTOKINE LEVELS (IL-6 AND IFN-γ), ACUTE PHASE RESPONSE AND NUTRITIONAL STATUS AS PROGNOSTIC FACTORS IN LUNG CANCERCytokine, 1999
- A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgeryThe American Journal of Surgery, 1995